Since its inception in 1984, the ability to understand, anticipate and respond to the oculoplastic research has resulted in FCI’s strong portfolio of globally recognized products. FCI offers innovative solutions essential in the treatment of dry eye, lacrimal, eyelid, and orbit indications.

Download

Date

March 4, 2021

File Size & Type

2.82 MB PDF

Categories